Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema

Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema

Abstract This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic mac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Takao Hirano, Yuichi Toriyama, Yoshihiro Takamura, Masahiko Sugimoto, Taiji Nagaoka, Yoshimi Sugiura, Fumiki Okamoto, Michiyuki Saito, Kousuke Noda, Shigeo Yoshida, Akihiro Ishibazawa, Osamu Sawada, Toshinori Murata
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/f5ae93ccb074428ea8a2b9a23ae71181
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f5ae93ccb074428ea8a2b9a23ae71181

Ejemplares similares